Want to see VYGR full AI Analyst Report?
VYGR Stock Chart & Stats
$3.48
$0.01(0.32%)
At close: 4:00 PM EDT
$3.48
$0.01(0.32%)
Day’s Range― - ―
52-Week Range$2.94 - $5.55
Previous CloseN/A
Volume484.46K
Average Volume (3M)481.19K
Market Cap
$208.27M
Enterprise Value$128.15
Total Cash (Recent Filing)$116.34M
Total Debt (Recent Filing)$32.57M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
Nov 10, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding61,617,947
10 Day Avg. Volume409,466
30 Day Avg. Volume481,195
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.18
Price to Sales (P/S)5.71
P/FCF Ratio-1.71
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.00Price Target Upside331.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.66
Revenue Forecast (FY)$41.20M
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressFDA IND clearance for VY1706 materially de-risks the preclinical-to-clinic transition and paves the way for clinical proof-of-concept. Over 2-6 months this enables enrollment, data generation and potential milestone triggers or partnering discussions that can transform capital needs and strategic optionality.
Robust Preclinical Efficacy & DeliverySix-month GLP non-human primate data showing broad CNS delivery, durable tau lowering up to 75% and favorable tolerability indicate strong translational potential of Voyager's vector and capsid platform. This durable evidence reduces biological risk and strengthens the company's competitive position in CNS gene therapy.
Financing Flexibility & GovernanceApproval to nearly double authorized shares plus re-election of directors signals shareholder endorsement and provides tangible capital-raising flexibility. Over months this structural change preserves the company's ability to access equity or transact strategically to fund clinical programs and partnerships without governance disruption.
Bears Say
Severe Cash BurnOperating cash flow swung from positive to a -$154M TTM outflow, reflecting rapid burn tied to clinical and R&D activity. Persistently negative cash generation over months erodes runway, forces dilutive financings or costly partnerships, and increases execution risk for multi-year CNS programs.
Collapsing Partner/Revenue BaseRevenue plunged from $250M to $34.5M TTM and margins moved from profit to sizable losses, indicating reduced partner/license income. Structurally lower contract revenue undermines internal funding capacity for trials, increasing dependency on external capital and partnership milestones to sustain programs.
Eroding Equity CushionShareholder equity has roughly halved over recent periods, shrinking the balance-sheet buffer. While leverage remains moderate, the declining capital base reduces financial flexibility, raises dilution risk on future financings, and could weaken negotiating leverage with partners or creditors over the next several quarters.
Voyager Therapeutics News
VYGR FAQ
What was Voyager Therapeutics’s price range in the past 12 months?
Voyager Therapeutics lowest stock price was $2.94 and its highest was $5.55 in the past 12 months.
What is Voyager Therapeutics’s market cap?
Voyager Therapeutics’s market cap is $208.27M.
When is Voyager Therapeutics’s upcoming earnings report date?
Voyager Therapeutics’s upcoming earnings report date is Nov 10, 2026 which is in 66 days.
How were Voyager Therapeutics’s earnings last quarter?
Voyager Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.484 by $0.084.
Is Voyager Therapeutics overvalued?
According to Wall Street analysts Voyager Therapeutics’s price is currently Undervalued.
Does Voyager Therapeutics pay dividends?
Voyager Therapeutics does not currently pay dividends.
What is Voyager Therapeutics’s EPS estimate?
Voyager Therapeutics’s EPS estimate is -0.42.
How many shares outstanding does Voyager Therapeutics have?
Voyager Therapeutics has 61,617,947 shares outstanding.
What happened to Voyager Therapeutics’s price movement after its last earnings report?
Voyager Therapeutics reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.484. Following the earnings report the stock price went up 4.473%.
Which hedge fund is a major shareholder of Voyager Therapeutics?
Currently, no hedge funds are holding shares in VYGR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Voyager Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (331.03% Upside)
$15.00 (331.03% Upside)
Blogger Sentiment
Bullish
VYGR Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 194.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-38.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Voyager Therapeutics
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
VYGR Stock 12 Month Forecast
Average Price Target
$15.00
▲(331.03% Upside)
Technical Analysis
Galectin Therapeutics
―
Cartesian Therapeutics
―
Silence Therapeutics
―
Tenaya Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
2.16% Insiders
9.54% Mutual Funds
17.20% Other Institutional Investors
60.52% Public Companies and
Individual Investors